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Limited English Proﬁcient Patients and Time Spent in Therapeutic
Range in a Warfarin Anticoagulation Clinic
Fatima Rodriguez, MD, MPH; Clemens Hong, MD, MPH; Yuchiao Chang, PhD; Lynn B. Oertel, MS, ANP; Daniel E. Singer, MD;
Alexander R. Green, MD, MPH; Lenny Lopez, MD, MPH, MDiv
Background-—While anticoagulation clinics have been shown to deliver tailored, high-quality care to patients receiving warfarin
therapy, communication barriers with limited English proﬁcient (LEP) patients may lead to disparities in anticoagulation outcomes.
Methods and Results-—We analyzed data on 3770 patients receiving care from the Massachusetts General Hospital
Anticoagulation Management Service (AMS) from 2009 to 2010. This included data on international normalized ratio (INR) tests
and patient characteristics, including language and whether AMS used a surrogate for primary communication. We calculated
percent time in therapeutic range (TTR for INR between 2.0 and 3.0) and time in danger range (TDR for INR <1.8 or >3.5) using the
standard Rosendaal interpolation method. There were 241 LEP patients; LEP patients, compared with non-LEP patients, had a
higher number of comorbidities (3.2 versus 2.9 comorbidities, P=0.004), were more frequently uninsured (17.0% versus 4.3%,
P<0.001), and less educated (47.7% versus 6.0% ≤high school education, P<0.001). LEP patients compared with non-LEP patients
spent less TTR (71.6% versus 74.0%, P=0.007) and more TDR (12.9% versus 11.3%, P=0.018). In adjusted analyses, LEP patients
had lower TTR as compared with non-LEP patients (OR 1.5, 95% CI [1.1, 2.2]). LEP patients who used a communication surrogate
spent less TTR and more TDR.
Conclusion-—Even within a large anticoagulation clinic with a high average TTR, a small but signiﬁcant decrease in TTR was
observed for LEP patients compared with English speakers. Future studies are warranted to explore how the use of professional
interpreters impact TTR for LEP patients. ( J Am Heart Assoc. 2013;2:e000170 doi: 10.1161/JAHA.113.000170)
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T he United States is increasingly diverse with growingpopulations of racial and ethnic minorities and immi-
grants, many of whom have difﬁculty communicating in
English. According to recent estimates, over 55 million
Americans, or 20% of the total population, speak a language
other than English at home.1 Of these individuals, over half
self-report speaking English less than “very well” and are
considered to have Limited English Proﬁciency (LEP).2
Patients with communication problems due to language
barriers are at high risk for preventable adverse events.3–7
Similarly, drug complications in outpatients are more common
in patients who speak a primary language other than English.8
Warfarin, a commonly prescribed anticoagulant, has a
narrow therapeutic range and therefore requires frequent,
long-term monitoring and close communication between
patients and providers. Warfarin is indicated for patients with
atrial ﬁbrillation and venous thromboembolism in order to
prevent ischemic stroke and other adverse outcomes.9,10 Low
literacy levels and limited English proﬁciency have been
associated with poor anticoagulation control.11–14 Monitoring
time in therapeutic range (TTR) can serve as an indicator of
the quality of anticoagulation and a surrogate for markers of
anticoagulation complications.13,15–18 Studies have demon-
strated that patients who spend less time in TTR are at
increased risk for serious bleeding complications, including
higher risk of intracranial hemorrhage.13,19,20 To our knowl-
edge, there have been no previous studies showing the
relationship between LEP status and TTR.
Due to the proven clinical importance of high-quality warfarin
control for preventing adverse outcomes, understanding how
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patients with communication barriers perform is of critical
importance. Using detailed clinical data from a large anticoag-
ulation clinic, we sought to answer 3 questions: (1) Do
differences in TTR exist between LEP and non-LEP patients?
(2) Are LEP patients more likely to spend time in the danger
range (ie, sub- or supratherapeutic international normalized
ratios [INRs]) comparedwith non-LEP patients? (3) Does the use
of communication surrogates impact TTR? Answering these
questions may have important implications for how warfarin
management clinics could be organized.
Methods
Study Population
The Massachusetts General Hospital Anticoagulation Man-
agement Service (AMS) is a large, nurse-run anticoagulation
service that provides comprehensive education on anticoag-
ulation management, monitors each patient’s INR, and
recommends follow-up dosing changes using standardized
protocols. Both primary care physicians and specialists, from
both inpatient and outpatient settings, refer patients to the
AMS. Patient follow-up is based on the prescribed duration of
warfarin therapy. Referring physicians complete annual ther-
apy reviews to conﬁrm the current treatment plan and
evaluate the risks and beneﬁts of continued therapy. AMS
uses a standardized process to monitor adherence, including
a series of automated reminder calls and letters to inform
patients of missed INR dates. AMS regularly uses medical
interpreters to collect information and deliver dosing infor-
mation to patients. AMS nurses collaborate with the referring
physician to promote adherence and safety and, as a result,
AMS discharges few patients for nonadherence.
We linked data from the AMS with the Research Patient
Data Repository (RPDR) through each patient’s unique
medical number. The RPDR gathers clinical information from
patients’ electronic medical records at various hospitals and
stores them in a central data registry.21 We obtained data on
patients who received care from AMS from January 1, 2009
through December 31, 2010 for all clinical indications with an
INR target between 2 and 3. We collected data on English
language proﬁciency, INR, patient sociodemographic charac-
teristics, site of primary care, and whether or not they used a
surrogate for primary communication with the providers.
Study Variables
Based on randomized trials and clinical guidelines, an INR
between 2.0 to 3.0 is the standard target anticoagulation
intensity for patients with atrial ﬁbrillation or venous throm-
boembolism.22,23 Using each patient’s INR data, we calculated
the time in therapeutic range (TTR deﬁned as time with an INR
between 2.0 and 3.0) and time in danger range (TDR deﬁned
as INR <1.8 or >3.5) for each patient using the standard
Rosendaal interpolation method.20,24 Prior research has
demonstrated that stroke risk for patients with AF increases
markedly at INR levels below 1.8 and the risk for intracranial
hemorrhage increases at INR levels above 3.5.19,20 We
deﬁned TTR as the number of person-days with an INR of
2.0 to 3.0 divided by the total number of person-days on
warfarin. This is presented as the average TTR for each
individual.
LEP patients were identiﬁed as those who reported
speaking English less than “very well,” as self-reported in
their registration documentation. Secondary predictors
included self-designated use of a communication surrogate,
deﬁned as a family member or other person identiﬁed as the
primary contact with whom AMS nurses communicate to
manage warfarin dosing and frequency of INR monitoring. A
communication surrogate is not limited to telephonic com-
munication with AMS, but may also have broader responsi-
bilities such as administration of warfarin, appointment
transportation, and other patient medical needs.
Sociodemographic variables included age, gender, race/
ethnicity (self-reported as white, Hispanic, black, Asian, other or
unknown), education (less than high school, high school or GED,
college, or more than college) and insurance status (commercial,
Medicare, Medicaid, self-pay, or free care).
A comorbidity index based on a count of comorbid
conditions was used for risk adjustment. We included
comorbid conditions present at enrollment to AMS based on
ambulatory billing data, as have been used by other
studies.25,26 These included atrial ﬁbrillation, chronic obstruc-
tive pulmonary disease, coronary artery disease, depression,
diabetes mellitus, congestive heart failure, hypertension,
osteoarthritis, or a cerebral vascular accident. This study
protocol was approved by the Massachusetts General Hos-
pital’s Institutional Review Board and informed consent was
waived since we analyzed deidentiﬁed, retrospective data.
Statistical Analyses
We compared LEP and non-LEP patient characteristics using
2-sample t tests or chi-square tests. We conducted bivariate
analyses to explore the associations between LEP status and
outcomes using 2-sample t tests for percent time in range and
chi-square tests for the percentage of patients above or below
a cutoff point.
We dichotomized TTR at 65% and TDR at 15% because
these levels are considered to represent adequate anticoag-
ulation control based on data from recent clinical trials.27 We
utilized multivariable logistic regression models to examine
the relationship between LEP status and these 2 dichotomized
outcomes, controlling for demographic and clinical covariates.
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We repeated the regression analyses stratiﬁed by LEP
status and the use of surrogates. SAS version 9.3 (SAS
Institute Inc) was used for all analyses. All reported P values
are 2-tailed and values <0.05 were considered statistically
signiﬁcant.
Results
Among 3770 total patients enrolled in the anticoagulation
clinic in 2009 and 2010, the most common primary indica-
tions for anticoagulation were atrial ﬁbrillation (68.4%) and
venous thrombosis or thromboembolism (14.1%) (Table 1).
There were 241 LEP patients in our sample (6.4%). LEP
patients, compared with non-LEP patients, were more likely to
be women (42.7% versus 30.1%, P=0.002), minorities (45.6%
versus 5.2%, P<0.001), underinsured (17.0% versus 4.3% with
Medicaid, free Care or self-pay, P<0.001), and less educated
(47.7% versus 6.0% with less than a high school education,
P<0.001), and had a higher number of comorbidities (3.2
versus 2.9, P=0.004).
The overall mean TTR for all patients enrolled in the AMS
clinic was 73.8% (median 76.1%). The overall TDR mean was
11.4% (median 8.6%). The primary predictor of TTR was LEP
status as a binary variable. In unadjusted analyses, LEP
patients had a lower mean TTR than non-LEP patients (71.6%
versus 74.0%, P=0.007) and a higher mean TDR (12.9% versus
11.3%, P=0.018) (Table 2). More LEP patients spent <65% of
the TTR as compared with non-LEP patients (27.8% versus
20.6%, P=0.008). LEP patients were also more likely to spend
more than 15% of total TDR as compared with non-LEP
patients (32.4% versus 24.3%, P=0.005).
After adjusting for sociodemographic and clinical factors,
LEP patients were more likely to spend less TTR (OR 1.5, 95%
CI 1.1, 2.2) but were not at greater risk of spending more TDR
(OR 1.3, 95% CI 0.9, 1.9) (Table 3).
A total of 585 patients (16% of the study sample) reported
using a communication surrogate, representing 61.4% of LEP
patients and 12.4% of the non-LEP patients. Patients who
Table 1. Study Population Characteristics (n=3770)
Characteristic
LEP
(n=241)
Non-LEP
(n=3529) P Value
Age, mean (SD) 73.0 (13.8) 71.5 (13.0) 0.12
Women, % 42.7% 30.1% 0.002
White, % 47.7% 89.2% <0.001
Insurance <0.001
Commercial 14.9% 20.5%
Medicare 49.8% 48.4%
Medicaid/self-pay/
free care
17.0% 4.3%
Less than high school
education
47.7% 6.0% <0.001
Comorbidity count,
mean (SD)
3.2 (1.5) 2.9 (1.6) 0.004
Surrogate, % 61.4% 12.4% <0.001
Indication for anticoagulation 0.11
Atrial fibrillation 70.5% 68.3%
Venous
thromboembolism
13.7% 14.2%
CVD/CAD 10.0% 8.3%
CHF 2.1% 1.4%
Valvular disease 2.1% 2.6%
Other 1.6% 5.2%
LEP indicates limited English proﬁcient; SD, standard deviation; CVD, cardiovascular
disease; CAD, coronary artery disease; CHF, congestive heart failure.
Table 3. Multivariable Logistic Regression Models*
Predictor
TTR <65%,
OR (95% CI)
TDR >15%,
OR (95% CI)
LEP vs non-LEP 1.5 (1.1, 2.2) 1.3 (0.9, 1.9)
LEP surrogate vs
non-LEP surrogate
1.2 (0.6, 2.2) 1.2 (0.6, 2.2)
LEP no surrogate vs
non-LEP no surrogate
1.5 (0.9, 2.6) 1.3 (0.8, 2.3)
LEP surrogate vs
LEP no surrogate
1.2 (0.6, 2.3) 1.2 (0.6, 2.2)
LEP surrogate vs
non-LEP no surrogate
1.8 (1.1, 2.8) 1.6 (1.1, 2.5)
TTR indicates time in therapeutic range; TDR, time in danger range; OR, odds ratio; CI,
conﬁdence interval; LEP, limited English proﬁciency.
*Adjusted for sociodemographic (age, gender, education, insurance) and clinical factors
(comorbidity counts).
Table 2. Time in Therapeutic Range and Time in Danger
Range for LEP Versus Non-LEP Patients
Characteristic LEP Non-LEP P Value
% TTR, mean (SD) 71.6 (13.1) 74.0 (13.9) 0.007
% TDR, mean (SD) 12.9 (10.2) 11.3 (11.0) 0.018
% Time INR <1.8,
mean (SD)
9.5 (8.8) 8.1 (9.5) 0.023
% Time INR >3.5,
mean (SD)
3.5 (3.5) 3.2 (4.2) 0.26
% of patients with
TTR <65%
27.8 20.6 0.008
% of patients with
TDR >15%
32.4 24.3 0.005
LEP indicates limited English proﬁciency; TTR, time in therapeutic range; TDR, time in
danger range; SD, standard deviation; INR, international normalized ratio.
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used a surrogate were older (mean age 77.1 versus 70.6,
P<0.001), more likely to be underinsured (7.5% versus 4.7%
with Medicaid, Free Care, or Self-pay, P<0.001), and more
likely to have less than a high school education (23.1% versus
6.1%, P<0.001). Additionally, these patients had a higher
comorbidity count as compared with patients without a
communication surrogate (3.3 versus 2.9, P=0.007). The
interaction analyses for LEP and surrogate use were signif-
icant for both TTR (P=0.0297) and TDR (P=0.005). There were
no signiﬁcant differences among LEP patients in TTR or TDR
with and without surrogate use. Both LEP and non-LEP
patients who used a communication surrogate spent less TTR
and more TDR, as compared with non-LEP patients who did
not use a communication surrogate (Table 3). As compared
with non-LEP patients without a surrogate, LEP patients who
used a surrogate were more likely to spend less TTR (OR 1.8,
95% CI [1.1, 2.8]) and a greater amount of TDR (OR 1.6, 95%
CI [1.1, 2.5]).
Discussion
Using data from a high-quality anticoagulation clinic, we found
that patients had a high average TTR at 74%. However, LEP
patients spent more time with suboptimal TTR and in TDR
compared with non-LEP patients. In adjusted analyses, LEP
patients spent signiﬁcantly more time in subtherapeutic INR
values <1.8. In addition, the use of a communication
surrogate was associated with less TTR and more TDR for
both LEP and non-LEP patients.
High-quality anticoagulation with warfarin demands com-
munication with patients and close monitoring of INR levels for
dose adjustment. Prior studies have documented that antico-
agulation clinics improve patient outcomes, with patients
spending more TTR and sustaining fewer complications.28–31
This suggests that a systematic approach for adherence to a
complex medication regimen with a narrow therapeutic
window such as warfarin may yield the best outcomes.
Nonetheless, we found signiﬁcant disparities for LEP patients
enrolled in the AMS clinic. Our study is one of the few to
explore the quality of anticoagulation among LEP patients
and supports evidence from prior studies that have docu-
mented higher adverse outcomes in patients with language
barriers.3–5,32–35 We found the largest disparity between LEP
patients compared with non-LEP among those with subthera-
peutic INR values <1.8. This is consistent with large, interna-
tional analyses of TTR that have demonstrated that the main
variation in INRs is among those patients at INR levels <2.0.36
Similar to other studies, our ﬁnding may be due to the fact that
there were very few participants who had INRs >3.5.
Interestingly, the use of a surrogates was associated with
more unfavorable anticoagulation proﬁles (lower mean% TTR
and higher mean% TDR) for LEP patients. For older LEP
patients, the use of a surrogate may indicate a particularly
vulnerable population who, in addition to having a language
barrier, may also face cognitive impairments and/or other
health literacy problems that further impede their ability to
adequately adhere to a complex medication regimen.14,37,38
Anticoagulation clinics should be aware that the use of a
surrogate might identify a higher-risk subset of patients who
may need closer and more intensive monitoring. For LEP
patients, surrogates may represent clinically untrained family
members who themselves also lack health literacy on warfarin
administration, side effects, and the importance of maintain-
ing a narrow therapeutic window. Not surprisingly, studies
have shown that the use of untrained ad hoc interpreters such
as family members and friends may lead to worse outcomes
for LEP patients.39,40
Our study suggests that, even in an AMS clinic with
excellent overall INR goal achievement, further strategies to
improve TTR for LEP patients are warranted. For example,
more intensive interventions such as language concordant
home visits, the use of patient navigators, education sessions
with the surrogate at the time of AMS enrollment, as well as
visual aids to promote improved patient comprehension may
provide useful adjuncts to existing AMS services.15,41 Alter-
natively, our study suggests that LEP patients, particularly
those who require a communication surrogate, may beneﬁt
from the use of newer anticoagulants that require less
intensive monitoring. Future studies should explore the role of
these newer anticoagulants for LEP patients who may ﬁnd it
particularly challenging to monitor and adjust their warfarin
dosing.42,43
There are several limitations to our study that warrant
mention. In our study, we were unable to account for the type
of surrogate used by patients or the exact communication and
management role of the surrogate with LEP patients.
Similarly, the use of data from a single anticoagulation clinic
at an academic institution limits generalizability to other
clinical settings. We were also unable to measure adverse
events (ie, bleeding or stroke) associated with sub- or
supratherapeutic anticoagulation. However, published studies
have documented the association of suboptimal TTR with
bleeding and stroke complications.13,19 Finally, we were
unable to take into account the intensity of contact with the
anticoagulation clinic during the study period.
Conclusion
Our study suggests that, overall, patients managed by a
dedicated anticoagulation clinic can achieve a high average
TTR. Still, a small but signiﬁcant disparity exists for LEP
patients, particularly those who require communication sur-
rogates. To our knowledge, there have been no previous
studies showing the relationship between LEP status and TTR.
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Future studies should further explore the proper role of
communication surrogates, including medical interpreters, in
reducing disparities for LEP patients taking warfarin anti-
coagulation, and the potential beneﬁt from more simpliﬁed
anticoagulation regimens that do not require intensive
monitoring.
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